Petra Education Company PLC (ASE:PEDC)

Verve Therapeutics Cash Flow Statement

Financials in millions JOD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	5.75	4.76	2.81	3.35	4.62	4.62
Depreciation & Amortization	1.99	2.03	2.25	2.37	2.23	2.05
Provision & Write-off of Bad Debts	0.2	0.2	0.24	0.25	0.15	0.1
Other Operating Activities	0.39	0.67	0.06	-0.21	0.08	-0.4
Change in Accounts Receivable	1.29	0.09	0.45	-0.65	-0.52	-0.31
Change in Inventory	-0.08	-0	-0.01	0.01	0.04	-0.06
Change in Accounts Payable	0.34	0.22	0.05	0.17	-0.45	-0.37
Change in Unearned Revenue	0.12	0.31	0.44	-0.23	-0.34	-1.24
Change in Other Net Operating Assets	-0.4	-0.27	-0.08	0.01	0.04	-0.61
Operating Cash Flow	9.6	8	6.22	5.07	5.85	3.79
Operating Cash Flow Growth	72.85%	28.64%	22.73%	-13.30%	54.37%	-46.94%
Capital Expenditures	-3.64	-2.46	-4.85	-1.79	-1.02	-1.26
Investment in Securities	-0.5	-0.5	-	-1	-	-
Investing Cash Flow	-4.14	-2.96	-4.85	-2.79	-1.02	-1.26
Common Dividends Paid	-4	-2.4	-2.4	-2	-3.2	-2.4
Financing Cash Flow	-4	-2.4	-2.4	-2	-3.2	-2.4
Net Cash Flow	1.46	2.64	-1.03	0.27	1.63	0.13
Free Cash Flow	5.96	5.54	1.37	3.27	4.83	2.53
Free Cash Flow Growth	140.97%	304.36%	-58.13%	-32.21%	91.00%	-40.87%
Free Cash Flow Margin	22.94%	22.44%	6.18%	14.28%	20.37%	10.51%
Free Cash Flow Per Share	0.30	0.28	0.07	0.16	0.24	0.13
Cash Income Tax Paid	0.28	0.86	0.89	1.31	1.34	1.82
Levered Free Cash Flow	4.79	4.56	0.78	2.59	3.91	1.8
Unlevered Free Cash Flow	4.79	4.56	0.78	2.59	3.91	1.8
Change in Net Working Capital	-1.86	-1.21	-1.16	0.65	1	2.83

Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.